Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer | Journal of Nuclear Medicine

Article Information

vol. 59 no. supplement 1 529

Published By

Society of Nuclear Medicine

Print ISSN

Online ISSN

History

Published online May 23, 2018.

Copyright & Usage

© 2018

Author Information

Harshad Kulkarni₁,
Christiane Schuchardt₁,
AVIRAL SINGH₁,
Thomas Langbein₁ and
Richard Baum₁

¹THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany

Statistics from Altmetric.com

Article usage

Article usage: May 2018 to August 2021

	Abstract	Full	Pdf
May 2018	5	0	0
Jun 2018	202	0	0
Jul 2018	318	0	0
Aug 2018	93	0	0
Sep 2018	346	0	0
Oct 2018	598	0	0
Nov 2018	427	0	0
Dec 2018	615	0	0
Jan 2019	767	0	0
Feb 2019	541	0	0
Mar 2019	543	0	0
Apr 2019	362	0	0
May 2019	407	0	0
Jun 2019	405	0	0
Jul 2019	517	0	0
Aug 2019	422	0	0
Sep 2019	301	0	0
Oct 2019	154	0	0
Nov 2019	112	0	0
Dec 2019	78	0	0
Jan 2020	74	0	0
Feb 2020	138	0	0
Mar 2020	123	0	0
Apr 2020	88	0	0
May 2020	43	0	0
Jun 2020	32	0	0
Jul 2020	19	0	0
Aug 2020	21	0	0
Sep 2020	57	0	0
Oct 2020	57	0	0
Nov 2020	52	0	0
Dec 2020	63	0	0
Jan 2021	77	0	0
Feb 2021	108	0	0
Mar 2021	127	0	0
Apr 2021	134	0	0
May 2021	72	0	0
Jun 2021	81	0	0
Jul 2021	114	0	0
Aug 2021	86	0	0

In this issue

Related Articles

Cited By...

Combination Strategies to Improve Targeted Radionuclide Therapy

Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

Show more Oncology, Clinical Diagnosis Track

Prostate: Therapy

Show more Prostate: Therapy

Similar Articles